Last summer, Tekton Research announced a strategic partnership with Summit Clinical Research to expand into MASH/NASH clinical trials—one of the most complex and high-demand areas in cardiometabolic research.
Less than a year later, that partnership is already delivering measurable results.
Early Momentum at Tekton’s Yukon, OK Site
The collaboration launched at Tekton’s Yukon, Oklahoma research site under Principal Investigator Dr. Robert Lockwood. Known for the operational complexity of MASH trials—from strict eligibility criteria to intensive protocol requirements—successful execution requires both strong infrastructure and experienced clinical leadership.
Tekton’s model, combined with Summit’s specialized support, was designed to meet that challenge. Within just five days of study activation, Dr. Lockwood and his team screened their first patient—an early indicator of both site readiness and strong patient access.
Why Speed Matters in MASH Trials
MASH (Metabolic dysfunction-associated steatohepatitis) trials are among the most demanding in clinical research. Delays in activation, patient identification, or screening can significantly impact timelines and costs.
This early milestone reflects more than speed—it demonstrates:
- Operational alignment between Tekton and Summit
- Physician-led patient identification, where investigators know their populations
- Prepared site infrastructure ready to execute from day one
Together, these elements reduce startup friction and accelerate progress where it matters most.
A Scalable Model for Cardiometabolic Research
Summit Clinical Research brings a proven framework for supporting MASH trials, including:
- Investigator onboarding and protocol training
- Regulatory and operational readiness
- Ongoing mentorship to ensure high-quality execution
Paired with Tekton’s physician-led, patient-connected site network, the partnership is designed to scale efficiently across new locations.
Expanding MASH Trial Access: New Carlisle, OH
Building on the early success in Oklahoma, Tekton is preparing to expand its MASH/NASH capabilities to additional sites.
The next activation is planned in New Carlisle, Ohio under Principal Investigator Dr. Ashok Devatha.
This expansion reflects a broader strategy: bringing high-quality MASH research to more communities while maintaining the same level of speed, consistency, and execution.
MASH Research: Looking Ahead
As MASH continues to emerge as a critical focus area in cardiometabolic research, Tekton’s partnership with Summit positions both organizations to play a meaningful role in advancing new therapies.
What started as a strategic collaboration is already translating into real-world performance—delivering faster activation, early patient engagement, and a strong foundation for continued growth.
About Tekton Research
Founded in 2006, Tekton Research is a multi-state clinical research site network conducting Phase 1-4 trials in CNS, cardiometabolic, general medicine and infectious disease. Led by seasoned professionals and nationally recognized KOLs, Tekton delivers scientific rigor and operational excellence across trials of any size. The company partners with sponsors, CROs, and biopharma to accelerate the development of new therapies while maintaining a strong commitment to patient-centered care.
About Summit Clinical Research
Summit Clinical Research is a premier international Integrated Research Organization (IRO) offering a full suite of services to support clinical development. With a network of 120 sites, Summit has been instrumental in advancing MASH and liver disease trials—consistently enrolling more than 50% of patients in global MASH studies while maintaining one of the lowest screening failure rates, significantly reducing costs for sponsors. Building on this success, Summit has expanded into obesity, cardiovascular disease, and Alzheimer’s—therapeutic areas well represented in its database and site network. Backed by leading KOLs, Summit has submitted over 500 abstracts and papers through direct efforts of its network and expert investigators.